Bevacizumab Gamma

CHEMBL5314727 Phase 4 معتمد Antibody
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

A biosimilar version of bevacizumab, the anti-VEGF monoclonal antibody used to treat cancers and neovascular eye diseases. Like the originator product, it inhibits blood vessel growth that tumors or abnormal eye tissue depend on for nutrients. Biosimilars offer comparable efficacy and safety at potentially lower cost.

المجالات العلاجية

آلية العمل

Binds to a specific target antigen on tumor cells or immune cells, triggering immune-mediated destruction through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or direct signaling inhibition.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Binds to a specific target antigen on tumor cells or immune cells, triggering immune-mediated destruction through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or direct signaling inhibition.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

A biosimilar version of bevacizumab, the anti-VEGF monoclonal antibody used to treat cancers and neovascular eye diseases. Like the originator product, it inhibits blood vessel growth that tumors or abnormal eye tissue depend on for nutrients. Biosimilars offer comparable efficacy and safety at potentially lower cost.

Binds to a specific target antigen on tumor cells or immune cells, triggering immune-mediated destruction through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or direct signaling inhibition.

Yes, Bevacizumab Gamma is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL5314727. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.